OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Cancer is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Computing brain metastasis impact	1665
Digging for treasures in the tumour interactome	1205
An inhospitable site	999
Fructose takes a detour to feed cancer	624
Implementing practice-changing progress for managing cancer of unknown primary	583
Exploiting metabolic cell death for cancer therapy	565
Oncofetal reprogramming in tumour development and progression	388
INVADEseq to study the intratumoural microbiota at host single-cell resolution	387
Emerging strategies to investigate the biology of early cancer	377
Combining spatial transcriptomics and AI to enhance brain tumour diagnosis	362
Combinatorial strategies to target RAS-driven cancers	353
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment	331
How medical anthropology can contribute to cancer research	325
Mapping the prostate cell family tree	323
Fighting cancer with fat	317
Reply to ‘Heterogeneity of TP53 mutations necessitates differentiation with p53-rescue therapies’	286
3D chromatin architecture as a predictor of somatic mutations in cancer genomes	281
Author Correction: Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma	263
Connie J. Eaves (1944–2024)	259
Antihistamines boost immunotherapy	251
The evolution of cancer and ageing: a history of constraint	235
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies	227
The recruitment of metastasis-associated monocytes	215
Translating premalignant biology to accelerate non-small-cell lung cancer interception	208
Context-dependent functions of pattern recognition receptors in cancer	205

Epithelial and stromal co-evolution and complicity in pancreatic cancer	204
Beyond genetics: driving cancer with the tumour microenvironment behind the wheel	201
Gut microbes produce novel genotoxic metabolites	197
Tertiary lymphoid structures as hubs of antitumour immunity	197
No mutation, tumour initiation	195
Nanoreceptors take down mutant p53	192
Impersonating neurons	187
Dendritic cells rise and shine	186
Tumour EVPs disrupt liver function	182
AACR 2025	173
Measuring HLA disruption using MHC Hammer	167
Persistence is key	166
Thelpers? More like Ttroublemakers	160
Removing barriers to address sex differences in anticancer drug toxicity	158
Remodelling of the tumour microenvironment by the kallikrein-related peptidases	156
Moonlighting functions of glucose metabolic enzymes and metabolites in cancer	149
Defining a ‘cells to society’ research framework for appendiceal tumours	146
3D bioprinted cancer models: from basic biology to drug development	140
How chemokines organize the tumour microenvironment	136
Natural killer cells in antitumour adoptive cell immunotherapy	130
Bone voyage: immune crosstalk sets sail	128
B-ring sterols to the rescue	126
In-depth organoid profiling of pancreatic cancer	123
Visualizing intratumoural heterogeneity with EpicMIBI	122
Identifying spatial cellular structures with SPACE-GM	120
The path to leptomeningeal metastasis	117
Points of entry for tumour-infiltrating lymphocytes	116
Regulatory T cells in the tumour microenvironment	115
Environmental endocrine disruptors: rethinking the origins of early-onset ER+ breast cancer	115
The immune microenvironment of colorectal cancer	112
Un-Fair Skin: racial disparities in acral melanoma research	112
Metabolic interplays between the tumour and the host shape the tumour macroenvironment	108
Leveraging the replication stress response to optimize cancer therapy	107
Dynamics and specificities of T cells in cancer immunotherapy	107
Linking cell mechanical memory and cancer metastasis	103
In situ decellularization of tissues to resolve the tumour-associated matrix	100
Race influences the tumour microbiome	97
Encoding spatial tumour dynamics with Starfysh	97
Understanding and addressing race disparities in childhood cancer outcomes	97
Deciphering the cancer genome and epigenome	96
The link between vitamin D and prostate cancer	91
Taming TAMs in brain metastases	89
Don’t blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemic	88
Cancer nanomedicine	84
Polygenic scores in cancer	83
RNA splicing dysregulation and the hallmarks of cancer	82
Acetyl-CoA metabolism in cancer	82
Targeted protein degradation for cancer therapy	81
Z-nucleic acids give immunotherapy a boost	78
Local CAR manufacturing	75

Parity modulates epithelial–immune cell communication	72
Right ON target: a new RAS-GTP inhibitor	69
Author Correction: Antibody-based proteomics: fast-tracking molecular diagnostics in oncology	69
Prime editing GEMMs to model cancer mutations	67
Integrative medicine in oncology: redefining the standard of care	66
Expanding the utility of precision oncology knowledge bases	65
NOTUM-mediated stem cell competition in CRC	64
Tamoxifen takes the wheel	62
A trojan horse to target spliceosome mutant cells	62
Defining precancer: a grand challenge for the cancer community	59
Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities	59
Tertiary lymphoid structures in anticancer immunity	54
Chromothripsis in cancer	51
Targeting ferroptosis as a vulnerability in cancer	49
Revealing genomic secrets of archival FFPE samples	47
In vivo labelling system to study cell neighbourhoods	47
Neutrophils: a roadblock for immunotherapy	47
Quantum probes in cancer research	45
Judith Campisi (1948–2024)	45
Functional lineage tracing to study the clonal evolution of therapy resistance	43
New pathogen on the block	42
Inferring cancer metabolism from gene-expression data	41
Glycogen condensates drive tumorigenesis by trapping Hippo kinases	40
Recent advances in therapeutic cancer vaccines	38
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart	38
The present and future of the Cancer Dependency Map	37
Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data	36
Carcinogenesis at single-cell resolution	35
Patient-derived organoids unveil sarcoma vulnerabilities	34
Bidirectional CART.BiTE cells bring new hope	34
Global post-mortem tissue donation programmes to accelerate cancer research	33
Focusing on the complex and dynamic interplay between ageing and cancer	31
Transfer RNAs as dynamic and critical regulators of cancer progression	31
Epigenomic heterogeneity as a source of tumour evolution	30
A timeline of tumour-associated macrophage biology	30
Developing dietary interventions as therapy for cancer	30
Digitally enhanced Raman spectroscopy	29
Author Correction: Integrative medicine in oncology: redefining the standard of care	29
Traject3d for studying 3D cellular heterogeneity	29
Mechanisms and treatment of cancer therapy-induced peripheral and central neurotoxicity	28
We cannot ignore the cancer risks of wildfires	27
Harnessing the influenza virus to fight cancer	26
Structural variations in cancer and the 3D genome	26